Bildkälla: Stockfoto

Amniotics: On the Way to the First Clinical Trial - Redeye

Redeye notes that Amniotics is following its plan to initiate its first clinical trial during H1 2022, after having handed in the CTA for PulmoStem in Covid-19.

Redeye notes that Amniotics is following its plan to initiate its first clinical trial during H1 2022, after having handed in the CTA for PulmoStem in Covid-19.
Börsvärldens nyhetsbrev
ANNONSER